Methadon maintenance treatment programs in Hungary: Treatment, Harm Reduction and Social Control by Rácz, József et al.
131New Medicine 
4/2012
© Borgis
regional studies on health science
o r i g i n a l  p a p e r s
Methadon Maintenance treatMent 
prograMs in hungary: treatMent, 
harM reduction and social control
*József rácz1, 2, 3, Ferenc Márványkövi1, 2, Katalin Melles1, Zsolt Petke2, 4, 
Viktória Vadász3, istván Vingender4
1Eotvos University, Institute of Psychology, Budapest, Hungary 
 Director of Institute: Dr Zsolt Demetrovics, PhD 
2Department of Addiction Medicine, Semmelweis University, Faculty of Health Sciences, Budapest, Hungary 
 Dean of Faculty: Dr Judit Mészáros, PhD 
3Blue Point Drug Counselling and Outpatient Centre, Budapest, Hungary 
 Director: Prof. Dr Jozsef Racz, PhD, DSc 
4Doctoral School, Semmelweis University, Faculty of Health Sciences, Budapest, Hungary 
 Program coordinator: Prof. Dr István Szabolcs, PhD, DSc 
5Semmelweis University, Department of Social Sciences, Faculty of Health Sciences, Budapest, Hungary 
 Dean of Faculty: Dr Judit Mészáros, PhD
summary
there are three drug policy strategies for methadone maintenance treatment programmes: treatment, harm reduction and so-
cial control. in this study we examine the hungarian methadone maintenance treatment programme. our objective is to arrive 
at recommendation that can also be applied to other countries in central and eastern europe, where these types of treatment 
do not currently exist. patients and experts from all eight hungarian clinics performing maintenance treatments were included 
in the research. the patients’ group was made up of 150 individuals, and the group of experts consisted of two professionals 
from each of the treatment facilities.
on the basis of our research observations we recommend the “opening up” of the maintenance system, as well as an approach 
that accords with the principles of treatment and harm reduction. these conclusions can be applied to other countries in the 
region, which had similar historical, political and professional policy factors in the past.
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INTRODUCTION
In this study we evaluate the national methadone 
maintenance treatment (MMT) programme of Hungary, 
a member of the European Union situated in central 
Europe (with a population of 10 million). Our main ob-
jective is to examine to what extent the Hungarian Na-
tional Guidelines for MMT (1) are kept. Another aim of 
the paper is to explore to what extent clients of the pro-
gramme are satisfied with the treatment and whether 
their treatment needs have been met properly. On the 
basis of the results, we will briefly make an attempt to 
determine whether the harm reduction paradigm is suc-
cessfully being carried out in MMT in Hungary. The rel-
evance of this study can be explained by the fact that 
MMTs, apart from a few exceptions, in the Central and 
Eastern European regions are less common and have 
a shorter operation history in comparison with Western 
European and overseas countries, whereas risky be-
haviours associated with intravenous use are relatively 
common in the Central and Eastern European regions 
(2-6). Another relevance of the study is that apart from 
one evaluation project (7), the Hungarian MMT had not 
been evaluated before.
Across the Eurasian region, all but five countries and 
territories have some form of Opioid Substitution Thera-
py (OST) provision. Programmes will soon begin oper-
ating in Tajikistan and Kosovo, but in Russia, Turkmeni-
stan, Kosovo and Uzbekistan (where a pilot OST site 
was shut down in June 2009) OST is not available. Even 
in regions where programmes exist, OST is accessible 
to less than 5% of opioid users, with some exceptions 
in Croatia, Slovenia, Hungary and the Czech Republic. 
In Eastern Europe and Central Asia, only 1% of people 
who inject drugs are reported to be receiving OST and 
OST programmes have generally remained at the pilot 
stage rather than systematically scale up (8).
The experience gained from our study can also be 
used in these countries where HIV infection related to 
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intravenous heroin use has reached an extremely high 
rate (in contrast to Hungary where HIV infection among 
injecting drug users are less than 1% (9)). The connec-
tion between HIV and injecting drug use are studied 
widely (e.g. 6, 10-15).
A EuroHIV (2007) report stated that “[i]n many western 
and central European countries, HIV prevalence is low 
and the proportion of new HIV diagnoses reported among 
IDU is <10% and decreasing” (16, p. 12). Furthermore, 
“[i]n some countries in the East, the HIV epidemic started 
to spread intensively more than a decade ago, and large 
and increasing numbers of new HIV diagnoses in several 
countries may reflect possible continuing transmission 
of HIV in this population, especially among younger IDU. 
In the East, increasing heterosexual HIV transmission 
partly is attributed to IDU partners” (16, p. 13).
Regarding HCV infection, in Hungary this rate in 
Budapest (the capital of Hungary with a population of 
two million residents) is around 35%, while elsewhere in 
the country it is under 20% (6, 17-23).
In the following section we will take a brief look at 
three different drug policy paradigms that are applied in 
MMTs worldwide.
Medical treatment – Brain disease Model
According to proponents of the medical treatment 
– brain disease model MMT is a medical treatment 
(24-27) and/or addiction is a brain disease (28, 29). 
The understanding of drug dependence as a “chronic 
disease” is represented most markedly by McLellan et 
al. (30). The summaries and international recommen-
dations cited in what follows interpret MMT within the 
context of the medical disease model and the treatment 
paradigm (31-35).
In those countries where MMT is considered a medi-
cal treatment, programmes have high threshold (36) as 
the admission criteria are strict. In Norway for example, 
the programmes are the part of the general health care 
and social services. The strict rules did not prevent the 
quick spread of the programme, or the inclusion of her-
oin users in Norway (36).
harm reduction as a Public health Model
The Harm Reduction (HR) model is only slightly dif-
ferent from the treatment model. The literature on HR 
emphasizes different areas of drug use and its conse-
quences in relation to MMT. The difference is slight in 
many cases because the same authors or international 
organizations employ both the “treatment” and the 
HR terms for MMT (or for other substitution therapies). 
Despite this, for didactic reasons, we strive to separate 
the two models from one another as much as possible.
Single (1995), who defines harm reduction as pro-
grammes “which attempt to reduce the harm associated 
with use, without the user giving up his or her use at the 
present time” and explicitly points out that “conceiving 
of harm reduction in this way means that abstinence-ori-
ented programs would not be considered harm-reduc-
tion measures” (37). The objective of the HR model is 
not achieving abstinence outside of methadone, but the 
reduction of individual and social harm related to heroin 
use (primarily infectious diseases, criminal behaviour, 
use of needles and drug mortality, etc.).
MMT (or more precisely opioid substitution therapy, 
OST) is one of the main forms of intervention for HR 
(8, 38). The experts of the European Monitoring Cen-
tre on Drugs and Drug Addiction place MMT within the 
context of HR, or the “new” public health approach 
(39). The Joint United Nations Programme on HIV/AIDS 
WHO, UNODC, & UNAIDS (2009) consider substitution 
therapies to be a “core set of HR” (40).
European programmes, and in particular the Dutch 
or Swiss maintenance programmes, are of this type 
(36, 39, 41). The programme presented by Millson et al. 
(2007) operates in Canada, within a needle exchange 
programme. The majority of the patients are recruited 
from amongst the visitors to the needle exchange pro-
gramme, for whom this is a step “forward” towards more 
intensive programmes with a higher threshold. Sweden 
for example has moved from the restrictive (“high thresh-
old”) model to a more tolerant (low threshold, public 
health) model, increasing the number of participants in 
MMT (and in buprenorphine treatment) (42). This has 
resulted in better retention and the reduction of certain 
kinds of harm related to heroin use.
Trautmann et al. (2007) reviewed the Slovenian 
methadone maintenance treatment system. This study 
is the closest to our study in terms of both the approach 
and the method, and because, like Hungary, Slovenia is 
a post-socialist country in central Europe (43). The as-
pects that they examined were related, in part, to the 
professional, political and ideological background of 
methadone treatment, they also characterized the 
treatment system and studied patient’s satisfaction in 
relation to methadone programmes. At the end of the 
research the authors did not emphasize the critical ele-
ments of the therapeutic system, but instead formulated 
recommendations on how it could be operated more ef-
fectively.
MMt as social control
In Keane (2009), MMT is analyzed, in a Foucaultian 
manner, as a regulatory technology that aims to create 
productive and obedient subjects. According to Keane, 
“[w]e can emphasise the social control of drug users 
through MMT” (44). This train of thought is expanded 
upon by Saris’s (2008) Irish example, where MMT is a 
part of governance, primarily for socially excluded popu-
lations (the author also examines how these populations 
construct a political or psychiatric drug discourse) (45). 
On the basis of street ethnographic studies, Bourgois 
concludes that:
[MMT] is an expression of the competition of con-
tradictory discourses: the criminalizing and healthiest 
versions of biopower that dominate in law enforcement, 
and popular culture, versus the ‘addiction-is-a-disease’ 
model that prevails in the biomedical establishment and 
emphasizes the pharmacological control of bodies. This 
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contradiction is reflected in the imposition by the legisla-
ture of repressive legal regulations that discourage high 
dosage prescriptions of methadone despite the em-
phatic consensus of federally-funded drug researchers 
that the biggest problem with most methadone clinics is 
the inadequately low doses they administer (70).
MMt in hungary
According to the Hungarian national drug strategies 
in 2009 and in 2000 (46, 47), MMT is primarily a HR, 
low threshold service, while according to the method-
ological policies developed by the profession (1, 48) it 
counts as treatment. While there is not a sharp differen-
tiation between these two approaches, the two docu-
ments (the National Drug Strategy and the guidelines 
developed by the College on Addictions, 2009) define 
MMT as a different drug policy tool. The first metha-
done treatment in Hungary was initiated in 1987, but it 
only became professionally and politically accepted in 
2001 (49).
Participants in substitution treatment in hungary
Following an initial increase in the number of patients, 
after 2005 their number did not increase; the financing 
system reached the boundaries of its capacity (tab. 2). 
Suboxone substitution treatment, an alternative to meth-
adone, began in 2007. It has several traits that make 
it preferable to methadone (50). In 2009 a total of 638 
patients were given MMT, while another 354 patients 
received a combined buprenorphine+naloxone therapy 
(20). A total of 57% of patients were treated at a single 
centre in the capital (20). MMT can only be offered in 
special outpatient centres that deal with alcohol and 
drug dependency. Methadone can only be prescribed 
by a psychiatrist or a doctor that specializes in addiction 
medicine (this latter qualification is generally acquired 
by psychiatrists). MMT is free, whereas buprenorphine-
naloxone therapy represents a significant expense for 
patients – at Hungarian prices – and therefore cannot 
reach those that need it most (20).
Between 2003 and 2006 the number of patients par-
ticipating in substitution treatment increased by 343%, 
and the 2006 figure then fell to 79% in 2008 (see ta-
ble 1). Budapest has the greatest proportion of patients 
participating in MMT. In Budapest, there are two cen-
tres, the biggest is the the Nyírő Gyula Hospital Outpa-
tient centre. This centre also collects and records the 
patients treated throughout the country (called National 
Methadone Register), using (since 2006) the Treatment 
Demand Indicator (TDI) (51).
the Ministry of health’s guidelines for MMt on 
methadone treatment and the objectives of harm 
reduction drug strategy
These guidelines for MMT (1, 48) outline the diagno-
sis and treatment indication considerations necessary 
Table 1. Participants in methadone substitution treatment.
Budapest outside Budapest total
2003 249 (Annual average) 0 249
2004 N.A. N.A. 377 (Annual average)*
2005 575 191 766
2006 672 181 853
2007 595 188 783
2008 467 210 677
2009 450 188 638
*80% from Budapest.
Table 2. The distribution of individuals included in the sample according to their treatment location and gender.
treatment location Male Female total 
Budapest, Nyírő Gyula Hospital 59 19 78
Soroksár Methadone Centre 18 5 23
Drogoplex (Budapest) 6 3 9
Miskolc Outpatient centre 13 1 14
Pécs Outpatient centre 2 1 3
Szeged Outpatient centre 13 5 18
Veszprém Outpatient centre 2 1 3
Eger 2 0 2
All treatment locations 115 35 150
Note: Interviews were conducted with two professionals from each of the treatment locations listed in this table.
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for methadone treatment (and thus for MMT too), as well 
as the features facilities must be qualified in providing 
MMT. The guidelines for MMT provide the registration of 
patients, the dose of methadone that can be given out 
(60-120 mg/day) and the amount that can be given out 
(and taken home). It also provides the other medical, 
health care and psychosocial services, as well as after-
care. We have already mentioned the general objectives 
of the national drug strategies in 2009 and in 2000 as 
they relate to HR (46, 47).
AIM OF THE STUDy
our research objectives were as follows:
1. To examine to which extent the treatment principles 
laid down in the guidelines for MMT (48) are being 
successfully carried out in practice, and the extent 
to which the expectations related to HR are being 
met (on the basis of the National Drug Strategy, 
2000-2009, 2009-2018 developed by the Ministry 
of youth and Sports (2001); and Ministry of Social 
and Labour Affairs (2010).
2. To examine to what extent clients of theMMT are 
satisfied with the programme.
MATERIAL AND METHODS
Participants
The data survey that we performed concerns two 
different target groups. The first group is the patients 
currently participating in a methadone maintenance 
treatment programme, the second is the directors of the 
programmes or the staff that provide methadone. A sin-
gle data survey was given to both target groups.
The inclusion criteria for the patients were that they 
must be older than 18 and must fulfil the quotas for in-
clusion in the sample group. We determined the frame-
work for the sample of patients on the basis of the sub-
stitution data for 2008. This contained the information on 
the proportions of patients on methadone maintenance 
in the national treatment locations in 2008, and the ra-
tio of men to women at the given treatment locations. 
The examiners at the given treatment locations selected 
the patients at random. Of all the treatment locations, 
patients from three locations in the capital and five loca-
tions from elsewhere in the country were included in the 
sample group (tab. 2).
During the course of study, 150 patients were in-
cluded in the sample group and a data survey was 
performed on 16 directors or professionals that pro-
vided methadone. Interviews took place at the treat-
ment locations. Before beginning the survey we pilot 
tested the patient questionnaire with five clients. Fol-
lowing this, the questionnaires for both the patients 
and the professionals started at the beginning of 
August 2009 and concluded at the end of Novem-
ber 2009. We performed the analysis of the results 
with the aid of SPSS. The ethics permit was issued by 
the Joint Psychological Research Ethics Committee 
(chairman: Dr. Gergely Csibra).
Method
The research we performed through the questioning 
of the target groups was carried out with the aid of two 
questionnaires. When developing the questionnaires 
(for the patients and the professionals) we used the 
“Evaluation of Self and Treatment” questionnaire (TCU 
Methadone Outpatient Form) (52) and the question-
naires used in the study by Trautmann et al. (2007) as 
a basis.
1. The patient’s satisfaction questionnaire (hereaf-
ter the patient’s questionnaire) was made up of 
16 pages of questions, which took approximately 
40-50 minutes to answer. The main sections of 
the patient’s questionnaire were: accessibility; 
the amount of and the frequency with which the 
methadone provided was used; the conditions 
of take-home methadone; rule violations through 
the failure to use it; attitudes to the staff providing 
methadone; information and sanctions related to 
following the protocol; and the health, social and 
psychosocial changes experienced by the pa-
tients.
2. The interview of the professionals was a 21 page 
questionnaire, which took approximately 60-90 
minutes to complete. During the course of the 
questioning, the professional evaluated the pro-
gramme. The main sections of the professional’s 
questionnaire were: description and characteris-
tics of the organization; the content characteris-
tics of the service; the professional staff; criteria 
of success; and knowledge of the guidelines for 
MMT.
During the course of the interviews, the patients 
were asked to provide their TDI code to avoid dupli-
cation of interviews (53). The TDI identification num-
ber (a number generated using the patient’s name 
and birth date) made the survey data anonymous 
insofar as it does not identify the individual. The ex-
aminers participating in the research were practicing 
social workers.
RESULTS
the Major socio-demographic characteristics 
of the sample (see table 3)
The major socio-demographic characteristics 
were as follows. The sample group comprised of 
76.7% males and 23.3% females. The average age 
in the sample was 33.8 years old. The largest group 
in the sample (26.7%) lived with parents or a com-
panion (as a couple). The next largest groups were 
those living alone (24%) and those living with a com-
panion and children (12%). The overwhelming ma-
jority in the sample (92%) lived in stable conditions. 
Every individual in the sample was a Hungarian citizen. 
A total of 40% stated that they were unemployed, while 
30% had regular employment. A total of 14% were 
economically inactive, and another 14% had some 
other employment status. The majority (59.3%) had 
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a secondary school diploma, while 31.3% had fin-
ished primary school and 6% had a higher educational 
degree.
drug use characteristics
Of those questioned, 34% named methadone 
and 33.3% named heroin as their primary drug. Regard-
ing the use of secondary drugs, 28% used cannabis, 
21.3% methadone, 14% alcohol, 10% amphetamines, 
8% cocaine and 7.3% heroin, while 43.3% smoke.
The beginning of their drug careers (the age at 
which they first used the primary drug) was, on av-
erage, 16.9 years of age. A total of 22% began us-
ing drugs before they were 15. The majority, 60.7%, 
stated that they used to inject but do not do so now, 
while 23.3% still inject. Of those remaining, 7.3% have 
never injected, while in 8% of the cases there was no 
information.
treatment characteristics
35.3% of the sample had never been to drug treat-
ment before, while 64.7% had. The minority, 24%, had 
not yet been in substitution treatment, while 76% had 
been in such treatment.
Regarding time spent in treatment, 21.8% had been 
in maintenance treatment for less than a year, 13.6% for 
2 years, 22.4% for 3-5 years, 27.2% for 4-10 years and 
15% for over 10 years.
The patients typically took 40mg (20 individuals, 
13.3%), 60 mg (27 individuals, 18%) or 80 mg (22 in-
dividuals, 14.7%) of methadone. Ten individuals took 
100 mg (6.7%), and there were patients (12 individuals, 
8%) that took 120 mg. The largest dose was 240 mg 
(in the case of one individual).
criteria for remaining in treatment
The majority of those questioned, 64% were pun-
ished because they took illegal drugs (bought in 
the streets). Of those questioned, 82.7% thought 
that the punishment was justified. Continuing the 
presentation of criteria for remaining in treatment, 
3.3% stated that if they were to continue treatment 
they were not allowed to be absent or stop attending. 
A similar number (54%) were not allowed to take illegal 
drugs ( bought in the streets) and 51% said they were 
not allowed to fight or show aggressive behaviour. 
According to 53%, they were not allowed to sell meth-
adone. The overwhelming majority of those ques-
tioned (84%) stated that there were regular urine or 
saliva drug tests during the treatment. According to 
49.6%, the tests were random. Of the respondents 
in treatment, 58% thought that the rules that were 
necessary for staying in treatment were not at all 
strict. Only 7.3% judged them to be slightly strict, and 
16% thought they were moderately or very strict. 
According to 20.6% of patients, it was not at all diffi-
cult to be admitted into the maintenance programme, 
12.6% thought it was slightly or moderately difficult, 
while 47.3% (nearly half) thought it was very difficult.
Table 3. The socio-demographic characteristics of the sam-
ple (N = 150), in percentages.
number 
of cases Percentage
gender
Male 115 76.7
Female 37 23.3
No information 0 0
age
18-29 years old 40 26.7
30-39 years old 80 53.3
40-49 years old 25 16.7
50+ years old 5 3.3
No information 0 0
Family situation
Living alone 36 24
Living with parents 40 26.7
Raising children alone 4 2.7
Living with a partner (as a couple) 40 26.7
Living with a partner and children 18 12
Living with friends 5 3.3
Other 7 4.7
No information 0 0
living conditions
Stable 138 92
Unstable 10 6.7
In an institute (prison, clinic) 0 0
No information 2 1.3
employment status
Regularly employed 45 30
Student 3 2
Economically inactive 21 14
Unemployed 60 40
Other 21 14
No information 0 0
highest educational degree
Did not attend/did not complete 
eight years of primary schooling 2 1.3
Primary school diploma 47 31.3
Secondary school diploma 89 59.3
College/university degree 9 6
No information 3 2
citizenship
Hungarian 150 100
Citizen of an EU member country 0 0
Other country 0 0
No information 0 0
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subjective changes
In this section patients described the changes they 
experienced in terms of their health, drug use and social 
issues (fig. 1).
Respondents were asked to rate the statements be-
low on a scale from 1 to 4. 1 stands for ‘I do not agree at 
all’, while 4 stands for “I absolutely agree”.
In general, it can be stated that patients report-
ed considerable positive changes in most areas 
with most mean scores exceeding 3. It seems that 
the treatment prevents clients from risk behavioural 
factors such as overdosing, excessive alcohol con-
sumption, amphetamine and heroin consumption as 
well as intravenuous use. The treatment also appears 
to facilitate the improvement of certain personal char-
acteristics and attitudes. At the same time it is inter-
esting to note that patients have been less successful 
in decreasing their medicine use (tranquilizers), drug 
use other than amphetamine and heroin and heroin 
craving.
Respondents also exprienced significant improve-
ments in their family and friend relationships, physical 
and mental status, whereas they are less confident 
whether their financial status and employment chances 
had improved.
attitudes towards the treatment staff (see figure 2)
Respondents were asked to rate the statements be-
low on a scale from 1 to 4. 1 stands for ‘I do not agree at 
all’, while 4 stands for “I absolutely agree”.
The opinion that the treatment workers do their 
jobs well is fairly clear-cut (average = 3.46), as well 
as that staff show understanding towards patients 
(average = 3.36), and patients’ trust in staff is above the 
median (average = 3.28). Clients strongly believe that 
they are treated equally by the staff (3.34) and relatively 
strongly agree with the fact that staying in the programme 
depends both on them and the staff (mean = 3.3). 
Respondents were also convinced that they are not 
looked down upon, embarrassed or disrespected by 
staff members.
Familiarity with the treatment protocol
38.6% of the respondents stated that they were pun-
ished for breaking treatment protocoles since they had 
been in treatment. The majority (64%) was punished for 
having taken drugs during treatment. Of those who had 
been punished, 82.7% admitted that the treatment staff 
was right in doing so.
53.3% of the sample stated that it was forbidden 
to miss the treatment session, 54% confessed taking 
Fig. 1. The subjective changes in patients during treatment.
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drugs, 51% stated being aggressive, while 53% admit-
ted having sold drugs during treatment. This seems to 
suggest that approximately only half of those in the treat-
ment were aware of the protocol. It is also interesting to 
note that 58% declared that the criteria reagarding being 
allowed to stay in treatment were not strict at all.
interviews of the Professionals
Amongst the institutions responding there were nine 
addictological out-patient clinics, six addictological care 
centres and one institution that combined both.
The hours of operation for a significant portion of 
the institutions did not differ, on average they opened 
at eight or nine a.m. and closed at three p.m. at the 
earliest and seven p.m. at the latest. Four of them 
were open on Saturdays and only two were open on 
Sundays.
In addition to emergency detoxification programmes, 
the respondents named the following additional objec-
tives: harm reduction (22.2%), achieving abstinence 
(16.7%), improving the quality of life (11.1%), restoring 
the ability to work (11.1%), social regulation (11.1%), 
and (5.6% each) reintegration, instilling the desire for 
change, facilitating everyday life, normal lifestyle and 
the continuance of maintenance treatment.
criteria of success
Those questioned typically considered the criteria 
of success to be the prevention of infectious diseases 
(16 experts), the reduction of illegal drug use (14 ex-
perts), the reduction of injecting (16 experts), the reduction 
of criminal behaviour (16 experts), remaining in long-term 
therapy (10 experts) and the development of motivation to-
wards abstinence oriented treatments (16 experts).
The minimum doses necessary to achieve the de-
sired substitution effect are shown in table 4.
Table 4. The minimum methadone doses that are consid-
ered necessary.
Frequency Percent
10 mg 1 6.3
20 mg 2 12.5
30 mg 3 18.8
40 mg 1 6.3
Changing 2 12.6
Total 9 100.0
DISCUSSION
During the course of the cross-section analysis 
of MMT in Hungary we sought out 150 patients and 
Fig. 2. Clients’ attitude towards staff.
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16 professionals as a part of a questionnaire study. 
The professionals worked at eight treatment locations, 
(we have eighth methadone centres in Hungary so they 
represented each centres). Our objective was to exam-
ine how and to what extent the treatment principles set 
down in the guidelines for MMT (1, 48) or the HR expec-
tations formulated in the two National Drug Strategies 
(46, 47) are implemented during the course of mainte-
nance treatments. It was also aimed to assess the ef-
ficiency of the Hungarian MMT through examining the 
level of satisfaction of the clients with the MMT.
Our previous research (54, 55) was reconfirmed by 
the fact that admittance to treatment is still not easy; 
nearly half of the sample judged it to be difficult. Also 
from our previous research (54) we know that there is 
great demand for admittance to MMT. The waiting pe-
riod – seemingly in contradiction to what we would have 
concluded from the previous data – was short (about 
half of the patients were admitted after one week). 
The difficulty of admittance is underscored by the fact that 
76% of the patients have already received MMT (there-
fore, it was not new patients that were admitted). These 
data do not support the expectations of the HR model.
According to the data, the patients enter MMT after 
a long period of drug use (average: 16.9 years), and 
on their own (so not through referral). The number of 
patients treated in MMT has shown a slow decrease in 
recent years, and most of the patients are treated in a 
single centre in the capital. Therefore, it cannot be said 
that MMT is easily accessible throughout the country.
The patients in our sample are characteristically 
given 40 mg, 60 mg or 80 mg of methadone, for 10 in-
dividuals the methadone dose is 100mg, and for 12 in-
dividuals it is 120mg. One in three patients receives a 
dose of more than 81mg. These data show similarities 
with the dosages observed in Slovenia (43), and are a 
little bit lower than doses in the United Kingdom (56). 
The effective dose is about 60-120mg (41, 48, 57). 
The Hungarian doses, which can be considered low, bring 
the effectiveness of the treatment and/or the achievement 
of HR objectives into question. The low doses also raise 
the question of how methadone maintenance treatment 
programmes assess themselves within the Hungarian 
maintenance programme, as genuine maintenance treat-
ment or a “long term” detoxification-style treatment (in the 
USA this period cannot be longer than 180 days) (58).
The overwhelming majority of those questioned 
(82%) stated that there were regular urine or saliva tests 
during treatment. At the same time the responses in re-
lation to how often these tests were performed proved 
to be rather dissimilar. From these responses we can 
conclude that the urine tests are occasional, while at the 
same time there are other MMTs where analysis of urine 
is regular  (59). The small percentage of supervised 
methadone administration theoretically strengthens the 
ties to HR.
According to the patients, after treatment began they 
had significantly fewer drug using friends and committed 
significantly fewer crimes, there was also a significant 
improvement in various variables and in the realm of 
physical/emotional condition. This is similar to patients 
in Slovenia (43). These factors underscore the mainte-
nance programmes’ effectiveness in HR. Those ques-
tioned do not crave heroin since they have been in the 
treatment, or more precisely they only report low-level 
cravings, and this is a change that includes elements of 
both the HR and treatment models. A positive result is 
that since entering the treatment patients’ large-scale al-
cohol consumption and overdoses have ceased. On the 
other hand, we can infer from the responses that drug 
use occurs during treatment (while the consumption 
of various medicines also increases). The latter result, 
seeing as we are talking about medicines that have the 
potential to be highly addictive (e.g. clonazepam), may 
relate to the methadone dosages and to access (or lack 
thereof) to psychosocial services.  A total of 40% of the 
patients are not satisfied with the hours of operation, 
which is a blow to the goal of easy access, and therefore 
to the objectives of HR.
As regards satisfaction with staff and treatment envi-
ronment, respondents have generally expressed posi-
tive opinions, which is quite similar to the findings in 
Slovenia (43).
Opening hours and accessibility of the treatment cen-
tre are crucial issues. Clients basically do not consider 
accessing the outpatient centre as a problem. However, 
they are less satisfied with the opening hours, which 
seems to suggest that treatment centres take clients’ 
needs less into consideration when deciding on their 
opening hours despite the fact that it is clearly laid down 
in the Guidelines for MMT that clients should be given 
the opportunity to receive their doses at weekends as 
well. Only four centres are open on Saturdays, while two 
on Sundays.
Our findings regarding keeping and familiarity with 
the protocol are also ambiguous. Our data suggest 
that clients are less informed about the rules as well as 
the criteria of remaining in treatment although they had 
been asked to acknowledge and agree with these when 
signing the contract at the beginning of their treatment. 
It can be concluded that a considerable proportion of 
the clients are not properly informed about the criteria of 
being allowed to stay in treatment.
Although getting admission into the MMT has high 
criteria (at least this is what data suggest), the protocol 
does not make a clear statement whether MMT should 
be considered as a high or low-threshold service (al-
though staying in treatment is tied to strong criteria). 
Based on our findings as well as client needs and feed-
back, it can be said that there is a latent intention to 
consider MMTs as low-threshold, or at least the pos-
sibility to consider them as low-threshold, mainly re-
garding admission criteria. This however requires the 
acquisition of a different treatment paradigm, mainly 
on drug policy level.
While 82% declared that there were regular urine or 
saliva tests during treatment, respondents were less con-
fident in being able to tell how regular these testswere.
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Another criteria to stay in treatment was the prohibition 
of selling methadone. 16% stated that they had already sold 
methadone during treatment, which can be interpreted as a 
favourable figure, but at the same time it can be considered 
as a warning to the management and staff.
In the staff interviews, 22.2% emphasized HR and 16.7% 
treatment elements of MMT. Both are low values, and it 
may be presumed that the staff consider other factors to 
be more important (e.g., patients’ quality of life in 16.7%).
In our study we found data related explicitly to social 
control in connection with the doses. In accordance with 
the observations of Bourgois (2000), we suggest that 
the low methadone dose serves social control instead of 
treatment or HR. The supposed drug policy goal is the 
retention of “problematic” patients in a service, thereby 
controlling them, even if the methadone dose does not 
serve therapy or HR.
CONCLUSIONS
The data of our research do not completely fulfil the 
objectives of the HR, treatment or social control mod-
els. We observed a MMT that is isolated in the Hungar-
ian health care system (the low proportion of those re-
ferred from other branches, the low proportion of those 
referred onwards and the high proportion of those that 
have already had MMT). We also observed that MMT is 
implemented in a medical/health care environment where 
a high ratio of psychiatrists and family doctors decline to 
treat addicts, and in particular drug addicts (60). It is ques-
tionable whether that isolated programme can achieve 
the objectives that have been set for it in the guidelines 
for MMT (48) or in the national drug policy (46, 47).
The professional policy environment (49), the profes-
sional refusal to treat addicts (60), the factors contribut-
ing to admittance into MMT (it is primarily those that have 
already been treated that are admitted), as well as the 
frequency with which patients are referred to MMT or re-
ferred from MMT to other health and social services, or 
more precisely the lack of this, presents a picture of MMT 
functioning as a closed, isolated system. Here the objec-
tives of neither treatment, nor HR nor social control can be 
achieved. MMT can only be performed at clinics special-
ized in addiction – and not even at all of these – and these 
clinics comprise a closed system parallel to the out-patient 
psychiatric system (there are psychiatric clinics where ad-
dictological patients are not treated ‘per se’). This psychi-
atric system also functions in an isolated manner within 
Hungarian health care (61). These systems are set in one 
another like a Russian nesting doll, each having relative in-
dependence, their own system of institutions and groups 
of experts. The drawbacks of this “nesting doll” system – in 
addition to the unnecessary parallels and the high costs 
– are: its impenetrable nature (whether we consider the 
movement of patients or the mobility of the professionals); 
the significance of the institutions’ demands instead of the 
patients’ demands; the lack of structure with a centralized 
aspect; the maintenance of stigmatization and the difficul-
ties in working against this stigma. These considerations 
are also listed in the two national drug strategies (46, 47) 
and, on the political side, in the not yet adopted, national 
alcohol policy concept (62).
In the future it is necessary to strive to ensure that MMT 
is not enclosed within the present Hungarian drug policy. 
Along with other maintenance programmes, reaches the 
drug users that need it, giving them psychosocial assis-
tance in addition to medicinal treatment and making their 
social reintegration possible. We can call this process as 
“mainstreaming” of MMT into the psychiatric as well as 
into the health care in Hungary. For this, we must use 
other health care and social services, or must refer them 
to those that are performing these services. MMT is par-
ticularly important in the case of disadvantaged heroin 
users that are not admitted into the treatment system, as 
well as where public injection appears (63, 64). This low 
threshold model, which increasingly takes HR aspects 
into account, can also serve as a lesson for countries 
where professional or political impediments to MMT or 
other maintenance treatments exist (8).
In short, we can conclude that, in the future, the ter-
mination of the sharp opposition between the two ap-
proaches (HR and disease models) seems to be emerg-
ing (65, 66, 67). Peterson et al. (2008) emphasize that 
in the case of heroin users that have not been admitted 
into MMT, the public financing of MMT, as well as the 
increase in HR elements according to the concepts of 
the study (developing a low threshold), can increase the 
number of drug users that are admitted into the treat-
ment (68). Bevan comes to similar conclusions, and 
states that “[t]here is a pressing need that public health 
principles should in fact be the foundation of all drug 
treatment interventions, and that investment in drug 
treatment is sound public health policy” (69).
RECOMMENDATIONS
Based on our findings, recommendations are made 
concerning the current guidelines for MMT. The WHO 
guidelines (2) for MMT supplemented with psycho-so-
cial services can be considered as a base for an inte-
grated and multidisciplinary approach.
1. We recommend that MMT should be low-threshold 
in regard to programme entrance, whereas criteria 
for staying in the programme should be high-thresh-
old. This should be based not only on addictologi-
cal but also drug-policy – based concepts as well.
2. New goals exceeding the public health treatment 
paradigm have to be set up such as improving the 
client’s social, employment, educational, mental 
status, setting client’s recovery as an ultimate goal 
(“methadone assisted” recovery [30]), improving 
the client’s life quality.
3. The national guidelines for MMT should contain 
clear recommendations, that on top of MMT, what 
additional services are needed for clients in differ-
ent phases of the treatment. The main aim is to 
modify the current MMT paradigm and facilitate 
the development of a more complex service sys-
tem where health and social services are integrat-
ed. An other relevant aim is to guide MMT towards 
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the mainstream public health system, along with 
other addictological services.
4. We also recommend that evaluation tools devel-
oped for assessing the efficiancy and monitoring 
the efficiency of MMT should be used as it is already 
laid down in the national guidelines for MMT.
LIMITATIONS
During the course of measuring patient’s satisfaction 
we sought out 150 patients in methadone maintenance 
treatment. As described in the “Sampling Procedures” 
section, we determined the sample size on the basis of 
the National Substitution Data, which served as a kind of 
sampling quota. Therefore, the research sample reflects 
the national proportions in relation to the number and 
gender of patients treated. The development of the sam-
pling quota was made more difficult because we did not 
have another national database upon which to base our 
sampling quota in order to make it – and therefore our 
sample – more precise. The TDI data could have served 
as a good basis, but they are lacking or untrustworthy in 
many cases. Random selection was used to ensure the 
representative nature of the sample. At the same time, 
we would be able to make more confident statements if 
it had been possible to create a larger sample.
Finally, it may be stated that the validity of the re-
sponses given to the questions may have been influ-
enced by the fact that the interviews were performed in 
the treatment environment, at the treatment site (but not 
in the presence of the treatment staff). However, the in-
frastructure necessary for performing questioning at a 
different location was unavailable.
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NOTE
In 2011 the new government (established after the 
parliamentary election in 2010) withdrew the “Drug strat-
egy 2009” (Ministry of Social and Labour Affairs, 2010). 
At the time of writing there is not any valid drug strategy 
in the country.
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